**Core Concept**
Thromboxane A2 is a prostanoid derived from arachidonic acid through the cyclooxygenase pathway. It plays a crucial role in platelet aggregation and vasoconstriction, which are essential processes in hemostasis. Thromboxane A2 is synthesized by platelets and has a short half-life, making it a key player in the regulation of blood clot formation.

**Why the Correct Answer is Right**
Thromboxane A2 exerts its effects through the activation of thromboxane A2 receptors on platelet membranes, leading to an increase in intracellular calcium levels and subsequent platelet activation. This process involves the binding of thromboxane A2 to its specific receptor, which triggers a cascade of intracellular signaling events. Thromboxane A2 also causes vasoconstriction by stimulating the contraction of smooth muscle cells in blood vessels.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because thromboxane A2 is not a vasodilator; instead, it is a potent vasoconstrictor.
**Option B:** This option is incorrect because prostaglandin I2 (PGI2) is a vasodilator and inhibits platelet aggregation, whereas thromboxane A2 has the opposite effects.

**Clinical Pearl / High-Yield Fact**
Thromboxane A2 is often used as a marker of platelet activation in various clinical conditions, including atherosclerosis, myocardial infarction, and stroke. Its measurement can provide valuable insights into platelet function and the risk of thrombotic events.

**Correct Answer:** C. Thromboxane A2 is a potent vasoconstrictor and platelet aggregator, which plays a critical role in hemostasis.